Ranitidine recall:

The TGA has suspended the registration of all ranitidine medicines. Further information is available from the TGA safety alert. Ranitidine is included as a default premedication in eviQ protocols and alternative approaches should be considered based on assessment of individual patients, institutional policy and availability of alternative drugs [e.g. famotidine - see ID 3264 Premedication for prophylaxis of taxane hypersensitivity reactions (infusion related reactions and anaphylaxis)]. Refer to BOPA Position Statement - H2 antagonists in paclitaxel pre-medication regimens for more information.

This document is an evidence-based summary to complement treatment protocols and includes background and rationale for specific point of care actions. It is not intended to be a comprehensive literature review of all available evidence.

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:


24 Apr 2024